Rapid and robust transgenic high-grade glioma mouse models for therapy intervention studies

Clinical Cancer Research

Volumn 16, Issue 13, 2010, Pages 3431-3441

  De Vries, Nienke A ^a   Bruggeman, Sophia W ^a   Hulsman, Danielle ^a   De Vries, Hilda I ^a   Zevenhoven, John ^a   Buckle, Tessa ^a   Hamans, Bob C ^c   Leenders, William P ^c   Beijnen, Jos H ^b,d   Van Lohuizen, Maarten ^a   Berns, Anton J M ^a   Van Tellingen, Olaf ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; K RAS PROTEIN; LENTIVIRUS VECTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P19; PROTEIN P53; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; BLOOD BRAIN BARRIER; CANCER GRADING; CANCER INVASION; CANCER THERAPY; CLINICAL FEATURE; CONTROLLED STUDY; FOLLOW UP; GLIOMA; GLIOMA CELL; INTERVENTION STUDY; LOXP SITE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; STEREOTACTIC PROCEDURE; TRANSGENIC MOUSE; TUMOR XENOGRAFT;

ADP-RIBOSYLATION FACTORS; ANIMALS; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; GENES, P16; GENES, P53; GENETIC VECTORS; GLIOMA; LENTIVIRUS; MICE; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; TRANSFECTION;

EID: 77954227259     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-3414     Document Type: Article

References (48)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359:492-507.
2. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61: 215-25.
3. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007;170:1445-53.
4. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007; 21:2683-710.
5. Bansal K, Liang ML, Rutka JT. Molecular biology of human gliomas. Technol Cancer Res Treat 2006;5:185-94.
6. Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN. Molecularly targeted therapy for malignant glioma. Cancer 2007;110:13-24.
7. Claes A, Schuuring J, Boots-Sprenger S, et al. Phenotypic and genotypic characterization of orthotopic human glioma models and its relevance for the study of anti-glioma therapy. Brain Pathol 2008;18: 423-33. (Pubitemid 351782851)
8. Antunes L, Angioi-Duprez KS, Bracard SR, et al. Analysis of tissue chimerism in nude mouse brain and abdominal xenograft models of human glioblastoma multiforme: what does it tell us about the models and about glioblastoma biology and therapy? J Histochem Cytochem 2000;48:847-58.
9. Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene 2004;23:7267-73.
10. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004;64:7011-21.
11. Huse JT,Holland EC.Genetically engineered mousemodels of brain cancer and the promise of preclinical testing. Brain Pathol 2009;19:132-43.
12. Pfeifer A, Brandon EP, Kootstra N, Gage FH, Verma IM. Delivery of the Cre recombinase by a self-deleting lentiviral vector: efficient gene targeting in vivo. Proc Natl Acad Sci U S A 2001;98:11450-5.
13. Miura M, Tamura T, Mikoshiba K. Cell-specific expression of the mouse glial fibrillary acidic protein gene: identification of the cisand trans-acting promoter elements for astrocyte-specific expression. J Neurochem 1990;55:1180-8. (Pubitemid 20306017)
14. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001;29: 418-25.
15. Marino S, Krimpenfort P, Leung C, et al. PTEN is essential for cell migration but not for fate determination and tumourigenesis in the cerebellum. Development 2002;129:3513-22.
16. Meuwissen R, Linn SC, van der Valk M, Mooi WJ, Berns A. Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene 2001;20:6551-8.
17. Lyons SK, Meuwissen R, Krimpenfort P, Berns A. The generation of a conditional reporter that enables bioluminescence imaging of Cre/ loxP-dependent tumorigenesis in mice. Cancer Res 2003;63:7042-6. (Pubitemid 37413436)
18. Kemper EM, Leenders W, Kusters B, et al. Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies. Eur J Cancer 2006;42:3294-303.
19. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol 2006;1:97-117.
20. Pardridge WM, Boado RJ, Farrell CR. Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier. Studies with quantitative Western blotting and in situ hybridization. J Biol Chem 1990;265:18035-40.
21. Proescholdt MA, Heiss JD, Walbridge S, et al. Vascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brain. J Neuropathol Exp Neurol 1999;58:613-27.
22. Gorin F, Harley W, Schnier J, Lyeth B, Jue T. Perinecrotic glioma proliferation and metabolic profile within an intracerebral tumor xenograft. Acta Neuropathol 2004;107:235-44.
23. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
24. Jakobsson J, Lundberg C. Lentiviral vectors for use in the central nervous system. Mol Ther 2006;13:484-93.
25. Jakobsson J, Ericson C, Jansson M, Bjork E, Lundberg C. Targeted transgene expression in rat brain using lentiviral vectors. J Neurosci Res 2003;73:876-85.
26. Marumoto T, Tashiro A, Friedmann-Morvinski D, et al. Development of a novelmouse gliomamodel using lentiviral vectors. NatMed 2009;15:110-6.
27. Knobbe CB, Reifenberger J, Reifenberger G. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol 2004;108:467-70.
28. Guha A, Feldkamp MM, Lau N, Boss G, Pawson A. Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 1997;15:2755-65. (Pubitemid 28004565)
29. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995;80:179-85.
30. Lau N, Feldkamp MM, Roncari L, et al. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. J Neuropathol Exp Neurol 2000; 59:759-67.
31. Ellis CA, Vos MD, Howell H, Vallecorsa T, Fults DW, Clark GJ. Rig is a novel Ras-related protein and potential neural tumor suppressor. Proc Natl Acad Sci U S A 2002;99:9876-81.
32. Ding H, Roncari L, Shannon P, et al. Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res 2001;61: 3826-36.
33. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 2000;25:55-7.
34. Zhu Y, Guignard F, Zhao D, et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 2005;8:119-30.
35. Zheng H, Ying H, Yan H, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 2008; 455:1129-33.
36. The Cancer Genome Atlas Research Network*. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
37. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001;410:1111-6.
38. Momota H, Nerio E, Holland EC. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res 2005;65:7429-35.
39. Hu X, Pandolfi PP, Li Y, Koutcher JA, Rosenblum M, Holland EC. mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia 2005;7:356-68.
40. Hambardzumyan D, Amankulor NM, Helmy KY, Becher OJ, Holland EC. Modeling adult gliomas using RCAS/t-va technology. Transl Oncol 2009;2:89-95.
41. Wiesner SM, Decker SA, Larson JD, et al. De novo induction of genetically engineered brain tumors in mice using plasmid DNA. Cancer Res 2009;69:431-9.
42. Plate KH, Risau W. Angiogenesis in malignant gliomas. Glia 1995;15: 339-47.
43. Pronin IN, Holodny AI, Petraikin AV. MRI of high-grade glial tumors: correlation between the degree of contrast enhancement and the volume of surrounding edema. Neuroradiology 1997;39:348-50.
44. Gambarota G, Leenders W, Maass C, et al. Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI. Br J Cancer 2008;98:1784-9.
45. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
46. Roodink I, van der LJ, Kusters B, et al. Development of the tumor vascular bed in response to hypoxia-induced VEGF-A differs from that in tumors with constitutive VEGF-A expression. Int J Cancer 2006;119:2054-62. (Pubitemid 44423661)
47. Zhang W, Mojsilovic-Petrovic J, Andrade MF, Zhang H, Ball M, Stanimirovic DB. The expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J 2003;17: 2085-7.
48. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006;9:391-403.